Tet-Systems and Clontech
Webinar Series on Tet Technology
The Tet technology consists of a chimeric transactivator protein and a Tet-specific promoter which the transactivator binds to in response to the presence (Tet-On®) or absence (Tet-Off®) of the tetracycline analogue doxycycline.
The Tet systems turn the expression of a gene of interest on or off at will, in a dose-dependent and reversible manner. In particular, the fully reversible nature of the Tet technology has enabled breakthrough insights into mechanisms of learning in animals by the Kandel group, and in the field of oncology. Other recent applications include the expression of inhibitory RNAs, and inducible pluripotent stem cells.
This webinar series aims to provide additional insights into how to best use the Tet technology for controlling gene expression in eukaryotes.
Part 1: Studying the Function of Genes by Controlling their Expression
Speaker: Prof. Dr. Dr. h.c. Hermann Bujard, University of Heidelberg, Germany
Abstract: This webinar will give an introduction to the underlying principles of the Tet technology and the concept of gene regulation by tetracyclines. Professor Bujard will also discuss the development of the Tet Systems components over time and their advantages as well as giving a review of results obtained by using the technology in transgenic mice.
Part 2:Controlling Gene Expression in transgenic mice
Speaker: Dr. Kai Schönig, Central Institute of Mental Health, Mannheim, Germany
Abstract: The focus of this webinar is on the use of Tet technology in transgenic mice. Options on how to set up the Tet inducible system in mice will be discussed. Dr. Schönig will also present a number of in vivo applications which demonstrate the potential of this powerful technology.
Part 3: Tet system: selected applications
Speaker: Dr. Manfred Gossen, BCRT, Berlin, Germany
Abstract: In the third webinar, Dr. Gossen is focusing on applications of particular interest including conditional RNA interference, the generation of packaging cell lines for virus production and ‘High Throughput Screening’ systems.
Part 4: Getting started with Tet-inducible gene expression - Choosing the right system for your application
Speaker: Dr. Michael Elser, Product Manager, Clontech/Takara Bio Europe, France
Abstract: The last webinar of the series will guide researchers wishing to establish a Tet-inducible system through the different options available. Dr. Elser will present a typical experimental setup and the steps necessary to achieve optimal performance. He will also address some common pitfalls and how to circumvent them.
Part 5: Controlling pest insect populations using Tet-Off
Speaker: Dr. Luke Alphey, Chief Scientist, Oxitec Ltd., UK.
Abstract: Pathogens that cause dengue fever, malaria, and several other globally important diseases are transmitted by insects. Historically, insectides have been used in a bid to control their populations, but more recently researchers have turned to genetic approaches. Dr. Alphey and his co-workers have engineered mosquitoes to express dominant lethal genes under the control of the Tet-OffÂ® tetracycline transactivator. The insects develop normally in the lab where they are fed tetracycline, but when they are released into the wild (where there is no tetracycline) their progeny do not survive. Dr. Alphey will discuss his experiences taking such engineered insects through to successful field use.
Hyperlink : http://info.clontech.com/tet-webinar-series-recording-part5.html